ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5312ometendo-5312Research ArticleСтатьиArticlesЗначение раннего интенсивного контроля гликемии в профилактике осложнений сахарного диабета 2 типа(результаты исследования UKPDS и последующего 10-летнего наблюдения за его участниками)The impact of early intensive glucose control for prophylaxis of complications of type 2 diabetes mellitus (results of UKPDS study and 10-year follow-up study)UshkalovaE Aeushk@yandex.ruGushchinaYu Sh-UshkalovaE A-GuschinaYu. Sh-20091506200962№2 (2009)1218Copyright © Ushkalova E.A., Gushchina Y.S., Ushkalova E.A., Guschina Y.S., 20092009Ushkalova E.A., Gushchina Y.S., Ushkalova E.A., Guschina Y.S.Ushkalova E.A., Gushchina Y.S., Ushkalova E.A., Guschina Y.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5312

В настоящее время сахарный диабет (СД) является ведущим неинфекционным заболеванием, оказывающим значимое влияние как на качество и продолжительность жизни каждого пациента, так и являющимся тяжелым бременем для системы здравоохранения. Медико-социальная значимость сахарного диабета определяется широкой распространенностью заболевания в популяции и высоким риском развития специфических осложнений, обусловленных макро- и микрососудистыми поражениями. Согласно последним данным основным звеном развития всех специфических осложнений СД является хроническая гипергликемия, а также важную роль играют артериальная гипертензия и нарушение липидного спектра крови. В ходе многоцентрового рандомизированного контролируемого исследования UKPDS было изучено влияние уровня гликемии и артериального давления, а также основных методов их коррекции на развитие осложнений СД 2 типа. Результаты исследования UKPDS продемонстрировали значение интенсивного контроля гликемии и жесткого контроля АД для профилактики осложнений СД 2 и летальных исходов. Они позволили разработать современные рекомендации по ведению больных СД 2 и определить целевые уровни НbAlc (<7,0%) и АД (<130/80 мм). После окончания рандомизированной части исследования за его участниками проводилось 10-летнее наблюдение (10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes) с целью определить оказывает ли проведенная терапия долгосрочный эффект на осложнения СД 2 типа. Результаты этого наблюдения продемонстрировали сохранение благоприятного влияния интенсивной сахароснижающей терапии на риск осложнений СД и летальных исходов

At the present time diabetes mellitus (DM) is a main noninfectious disease that not only significantly influences quality of life and life expectancy of every patient but also represents a heavy burden for the healthcare system. Medico social significance of DM is defined by high prevalence of this disease in population and high risk of its specific macro- and microvascular complications. According to latest data the main chain in the development of all specific complications of DM is chronic hyperglycemia, the important role belongs also to arterial hypertension and dyslipidemia. The multicenter randomized controlled study UKPDS assessed the influence of levels of hyperglycemia and arterial pressure as well as common methods of their corrections on development of complications of type 2 DM. The results of the UKPD study showed the significance of the intensive control of blood glucose and arterial pressure for the prophylaxis of type 2 DM complications and lethal outcomes. These observations allowed development of contemporary recommendations for treatment patients with type 2 DM and defined the target levels of HbAlc (<7,0%) and arterial pressure (<130/80 mm Hg). After the end of the randomized part of the study its participants were observed for 10 years (10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes) to investigate does the intensive therapy have long-term effect on complications of type 2 DM. The results showed the maintenance of positive effects of intensive glucose lowering therapy on the risk of DM complications and lethal outcomes.

сахарный диабетсосудистые осложненияуровень гликемииартериальное давлениеdiabetes mellitusvascular complicationslevel of glycemiaarterial pressureReferencesSherifali D., Punthakee Z. To lower or not to lower? Making sense of the latest research on intensive glycaemic control and cardiovascular outcomes. Evidence-Based Nursing 2009;12:4-6.Sherifali D., Punthakee Z. To lower or not to lower? Making sense of the latest research on intensive glycaemic control and cardiovascular outcomes. Evidence-Based Nursing 2009;12:4-6.National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2005.National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2005.Gu, K.; Cowie, C.C.; Harris, M.I. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care. 1998; 21:1138-45.Gu, K.; Cowie, C.C.; Harris, M.I. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care. 1998; 21:1138-45.Gu, K.; Cowie, C.C.; Harris, M.I. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care. 1998; 21:1138-45.Gu, K.; Cowie, C.C.; Harris, M.I. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care. 1998; 21:1138-45.Muhammad S. Epidemiology of diabetes and obesity in the United States. Compend Contin Educ Dent 2004; 25(3):195-98, 200, 202.Muhammad S. Epidemiology of diabetes and obesity in the United States. Compend Contin Educ Dent 2004; 25(3):195-98, 200, 202.Garcia, M.J.; McNamara, P.M.; Gordon, T.; Kannel, W.B. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes. 1974; 23: 105-11.Garcia, M.J.; McNamara, P.M.; Gordon, T.; Kannel, W.B. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes. 1974; 23: 105-11.Schnell O., Hummel M., Weber C. Economic and clinical aspects of diabetes regarding self-monitoring of blood glucose. Diabetes Technol Ther. 2008 Jun;10 Suppl 1:S72-81.Schnell O., Hummel M., Weber C. Economic and clinical aspects of diabetes regarding self-monitoring of blood glucose. Diabetes Technol Ther. 2008 Jun;10 Suppl 1:S72-81.American Diabetes Association: Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31:596-615, 2008.American Diabetes Association: Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31:596-615, 2008.Rizza R., Eddy D., Kahn R. Cure, care, and commitment: what can we look forward to? Diabetes Care 31:1051-1059, 2008.Rizza R., Eddy D., Kahn R. Cure, care, and commitment: what can we look forward to? Diabetes Care 31:1051-1059, 2008.Genuth S.The UKPDS and its global impact. Diabet Med. 2008 Aug; 25 Suppl 2:57-62.Genuth S.The UKPDS and its global impact. Diabet Med. 2008 Aug; 25 Suppl 2:57-62.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinediones. Diabetologia. 2008; 51: 8-11.Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinediones. Diabetologia. 2008; 51: 8-11.Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes.N Engl J Med. 2008 Oct 9; 359(15): 1577-89.Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes.N Engl J Med. 2008 Oct 9; 359(15): 1577-89.Holman R.R., Paul S.K., Bethel M.A., Neil H.A., Matthews D.R. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008 Oct 9; 359(15): 1565-76.Holman R.R., Paul S.K., Bethel M.A., Neil H.A., Matthews D.R. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008 Oct 9; 359(15): 1565-76.Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 22: 2643-53.Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 22: 2643-53.The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993;329:997-86.The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993;329:997-86.Gerstein H.C., Miller M.E., Byington R.P., et al. Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008; 358:2545-2559.Gerstein H.C., Miller M.E., Byington R.P., et al. Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008; 358:2545-2559.Patel A., MacMahon S., Chalmers J., et al. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008; 358:2560-2572.Patel A., MacMahon S., Chalmers J., et al. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008; 358:2560-2572.Duckworth W., Abraira C., Moritz T., et al. The VADT Investigators. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2008 Dec 17. [Epub ahead of print]Duckworth W., Abraira C., Moritz T., et al. The VADT Investigators. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2008 Dec 17. [Epub ahead of print]Goh S.Y., Cooper M.E. The role of advance glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-52.Goh S.Y., Cooper M.E. The role of advance glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-52.EXPERT CONSENSUS DOCUMENT. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. J Am Coll Cardiol, doi:10.1016/j.jacc.2008.10.008 (Published online 17 December 2008).EXPERT CONSENSUS DOCUMENT. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. J Am Coll Cardiol, doi:10.1016/j.jacc.2008.10.008 (Published online 17 December 2008).

The authors declare that there are no conflicts of interest present.